Evommune

Congratulations to Dr. Eugene Bauer, our Chief Medical Officer, on receiving the Discovery Award, an honorary award by The Dermatology Foundation, for your remarkable research accomplishments impacting patients living with inflammatory diseases. It is a well-deserved and rarely given recognition. Evommune is fortunate to have such an accomplished clinician on our team, as we advance development of new treatments for patients suffering from chronic inflammatory diseases.  American Academy of Dermatology Dermatology Foundation Dermatology Times

Congratulations to Dr. Eugene Bauer, our Chief Medical Officer, on receiving the Discovery Award, an honorary award by The Dermatology Foundation, for your remarkable research accomplishments impacting patients living with inflammatory diseases. It is a well-deserved and rarely given recognition. Evommune is fortunate to have such an accomplished clinician on our team, as we advance development of new treatments for patients suffering from chronic inflammatory diseases.  American Academy of Dermatology Dermatology Foundation Dermatology Times

We are proud to sponsor the 2025 Dermatology Innovation Forum, hosted by @Advancing Innovation in Dermatology! Please stop by our booth to learn more about Evommune and our efforts to deliver new treatment options for patients suffering from chronic inflammatory diseases.  #DIF2025 #AdvancingDerm #Dermatology

The Evommune team will attend the Leerink Partners Global Healthcare Conference in Miami and is available for one-on-one meetings on Tuesday, March 11. We hope to see you there! Kyle Carver Luis Peña Mark Jackson

The Evommune team is looking forward to participating in the Guggenheim Biotech Conference this week, which includes the panel discussion "Taming the Inflamed: Novel Approaches to Treating Inflammatory Diseases" with our CEO, Luis Pena, on Thursday, February 6, from 11-11:55 a.m. EST. We'll see you there!

We are proud to be a sponsor of the 2025 Dermatology Summit hosted by @Advancing Innovation in Dermatology! We look forward to participating in this year's conference, where Mark Jackson, our Vice President of Clinical Development, will participate in a fireside chat centered on mast cell therapies.   The 2025 Dermatology Summit brings together members of the financial community and business leaders from established and emerging companies in the dermatology space. You can register for the conference on January 12th here: https://lnkd.in/gkjuR8mg   #DermatologySummit #AdvancingDerm #Dermatology

Check out Mark Jackson Q&A with Dermatology Times on proof-of-concept trial results with our investigational oral MRGPRX2 antagonist, EVO756. #inflammation #urticaria #biotechnology #atopicdermatitis

We’re pleased to announce today’s podium clinical presentation by Romi Saini at the 7th GA²LEN Global Urticaria Forum in Berlin. Data from our first-in-human proof-of-concept trial suggests the potential of EVO756 as a first and best-in-class opportunity for patients suffering from various mast cell-mediated diseases, including urticarias. Check out today’s press release for more information: https://lnkd.in/gX6B4jqD

Our President and CEO, Luis Pena, will be in Miami on December 4-5th for the 7th Annual Evercore ISI HealthCONx Conference and Citi’s 2024 Global Healthcare Conference. We hope to see you there!

We look forward to the upcoming JP Morgan Healthcare Conference in our hometown.